ChromaDex Corporation

(NASDAQ:CDXC)

Latest On ChromaDex Corporation (CDXC):

Date/Time Type Description Signal Details
2023-05-12 07:25 ESTNewsChromaDex Corporation (CDXC) Q1 2023 Earnings Call TranscriptN/A
2023-05-11 03:05 ESTNewsChromaDex GAAP EPS of -$0.03 beats by $0.02, revenue of $22.56M beats by $3.24MN/A
2023-05-10 01:05 ESTNewsChromaDex Q1 2023 Earnings PreviewN/A
2023-03-17 22:06 ESTNewsChromaDex (CDXC) Investor Presentation - SlideshowN/A
2023-03-09 14:24 ESTNewsChromaDex Corporation 2022 Q4 - Results - Earnings Call PresentationN/A
2023-03-08 23:37 ESTNewsChromaDex GAAP EPS of -$0.02 beats by $0.01, revenue of $21M beats by $0.12MN/A
2023-03-08 23:36 ESTNewsChromaDex Corporation (CDXC) Q4 2022 Earnings Call TranscriptN/A
2023-01-05 21:16 ESTNewsChromaDex appoints Brianna Gerber as CFON/A
2022-11-17 02:32 ESTNewsChecking Into ChromaDexN/A
2022-11-03 06:49 ESTNewsChromaDex Non-GAAP EPS of -$0.04 beats by $0.02, revenue of $17.06M misses by $1.68MN/A
2022-11-03 06:48 ESTNewsChromaDex Corporation (CDXC) Q3 2022 Earnings Call TranscriptN/A
2022-11-01 23:37 ESTNewsChromaDex Q3 2022 Earnings PreviewN/A
2022-10-11 13:35 ESTNewsChromaDex inks new commercial supply agreement for its Niagen ingredient with NestléN/A
2022-10-03 23:50 ESTNewsChromaDex forms JV in Asia for Tru Niagen; plans to raise $3.1M via stock saleN/A
2022-09-01 20:41 ESTNewsChromaDex in pact to introduce anti-aging compound in BrazilN/A
2022-08-24 18:22 ESTNewsAyana Bio appoints Frank Jaksch as CEON/A
2022-08-16 22:43 ESTNewsChromaDex downgraded at Oppenheimer citing further pressure on toplineN/A
2022-08-15 12:35 ESTNewsChromaDex wins patent challenge as US regulator rejects Thorne Research's demand to invalidate patentN/A
2022-08-12 00:17 ESTNewsChromaDex stock falls 17% as Q2 sales decline missing estimatesN/A
2022-08-11 07:21 ESTNewsChromaDex GAAP EPS of -$0.09 in-line, revenue of $16.7M misses by $2.19MN/A
2022-08-11 07:21 ESTNewsChromaDex Corporation (CDXC) CEO Robert Fried on Q2 2022 Results - Earnings Call TranscriptN/A
2022-08-09 20:45 ESTNewsChromaDex Q2 2022 Earnings PreviewN/A
2022-06-10 15:29 ESTNewsChromaDex teams up with Sinopharm for sales of anti-ageing product in ChinaN/A
2022-06-02 23:11 ESTNewsChromaDex team up with Juvenis for sales of Tru Niagen in South KoreaN/A
2022-05-19 18:35 ESTNewsChromaDex stock gains postmarket on JV to distribute supplement in ChinaN/A
2022-05-14 13:17 ESTNewsChromaDex Corporation 2022 Q1 - Results - Earnings Call PresentationN/A
2022-05-13 08:30 ESTNewsChromaDex GAAP EPS of -$0.11 misses by $0.02, revenue of $17.26M misses by $0.26MN/A
2022-05-13 08:30 ESTNewsChromaDex Corporation (CDXC) CEO Rob Fried on Q1 2022 Results - Earnings Call TranscriptN/A
2022-05-11 20:50 ESTNewsChromaDex Q1 2022 Earnings PreviewN/A
2022-03-17 04:18 ESTNewsChromaDex gets additional US patent related to NiagenN/A
2022-03-11 08:41 ESTNewsChromaDex Corporation's (CDXC) CEO Rob Fried on Q4 2021 Results - Earnings Call TranscriptN/A
2022-03-10 13:37 ESTNewsChromaDex Corporation (CDXC) CEO Rob Fried On Q4 2021 Results - Earnings Call TranscriptN/A
2022-03-10 13:36 ESTNewsChromaDex stock falls 14% following Q4 resultsN/A
2022-03-09 21:15 ESTNewsChromaDex GAAP EPS of -$0.08 beats by $0.02, revenue of $17.8M misses by $0.97MN/A
2022-03-09 21:15 ESTNewsChromaDex Corporation 2021 Q4 - Results - Earnings Call PresentationN/A
2022-03-09 04:30 ESTNewsChromaDex Q4 2021 Earnings PreviewN/A
2022-03-02 14:48 ESTNewsChromaDex's Niagen supplementation shows promise in Parkinson’s disease trialN/A
2022-02-09 08:58 ESTNewsChromaDex granted U.S. patent related to NiagenN/A
2022-01-20 17:14 ESTNewsChromaDex in pact with Designs for Health to offer new Niagen-formulated productsN/A
2021-11-04 05:42 ESTNewsChromaDex EPS misses by $0.04, beats on revenueN/A
2021-11-04 05:42 ESTNewsChromaDex Corporation (CDXC) CEO Rob Fried on Q3 2021 Results - Earnings Call TranscriptN/A
2021-10-18 10:16 ESTNewsChromaDex's Niagen ingredient benefits children with neurodegenerative disorder in studyN/A
2021-10-12 22:10 ESTNewsWarning: CDXC is at high risk of performing badlyN/A
2021-10-07 06:55 ESTNewsCDXC is at high risk of performing badlyN/A
2021-09-29 11:52 ESTNewsChromaDex inks Tru Niagen partnership with Sinopharm Xingsha in ChinaN/A
2021-09-27 14:40 ESTNewsWarning: CDXC has been downgraded to Very BearishN/A
2021-09-22 23:31 ESTNewsWarning: CDXC has been downgraded to Very Bearish.N/A
2021-09-17 15:59 ESTNewsChromaDex plunges despite plans to appeal court ruling in patent infringement caseN/A
2021-08-05 01:43 ESTNewsChromaDex Corporation 2021 Q2 - Results - Earnings Call PresentationN/A
2021-08-04 04:21 ESTNewsChromaDex Corporation (CDXC) CEO Rob Fried on Q2 2021 Results - Earnings Call TranscriptN/A

About ChromaDex Corporation (CDXC):

ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and IMMULINA, a Braun-type lipoproteins, including spirulina extracts and active compounds, which are used to support human immune function. It also offers analytical reference standards and services comprising supply of products to conduct quality control of raw materials and consumer products in dietary supplements, cosmetics, food and beverages, life sciences, and pharmaceutical industries. The company distributes TRU NIAGEN products direct to consumers through its propriety ecommerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation is headquartered in Los Angeles, California.

See Advanced Chart

General

  • Name ChromaDex Corporation
  • Symbol CDXC
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 110
  • Last Split Factor1:3
  • Last Split Date2016-04-13
  • Fiscal Year EndDecember
  • IPO Date2008-07-15
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryLife Sciences Tools & Services
  • Gic SubIndustryLife Sciences Tools & Services
  • Web URLhttp://www.chromadex.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 12.03
  • Price/Book (Most Recent Quarter) 38.43
  • Enterprise Value Revenue 12.41
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$0.27
  • Next Year EPS Estimate -$0.03
  • Next Quarter EPS Estimate -$0.06
  • Profit Margin -34%
  • Operating Margin -34%
  • Return on Assets -32%
  • Return on Equity -108%
  • Revenue 59.26 million
  • Earnings Per Share -$0.60
  • Revenue Per Share $0.97
  • Gross Profit 35.27 million
  • Quarterly Earnings Growth 18%
View More

Highlights

  • Market Capitalization 770.17 million
  • EBITDA -31444000
  • Analyst Target Price $16
  • Book Value Per Share $0.27
View More

Share Statistics

  • Shares Outstanding 66.74 million
  • Shares Float 46.59 million
  • % Held by Insiders 3796%
  • % Held by Institutions 25.12%
  • Shares Short 2.16 million
  • Shares Short Prior Month 2.01 million
  • Short Ratio 0.3
  • Short % of Float 4%
  • Short % of Shares Outstanding 3%
View More

Technicals

  • Beta 1.81
  • 52 Week High $16.82
  • 52 Week Low $2.5
  • 50 Day Moving Average 8.96
  • 200 Day Moving Average 5.8
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

ChromaDex Corporation (CDXC) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

ChromaDex Corporation (CDXC) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-10$N/A-$0.11-$0.10-11.9%
2020-09-302020-11-04$N/A-$0.07-$0.0922.22%
2020-06-302020-08-06$N/A-$0.06-$0.1037.95%
2020-03-312020-05-11$14.35 million-$0.10-$0.116.98%
2019-12-312020-03-10$13.09 million-$0.11-$0.112.22%
2019-09-302019-11-12$12.05 million-$0.12-$0.12-4.35%
2019-06-302019-08-07$11.1 million-$0.14-$0.13-5.03%
2019-03-312019-05-09$10.05 million-$0.15-$0.12-28.53%
2018-12-312019-03-07$9.07 million-$0.15-$0.14-9.73%
2018-09-302018-11-07$8.12 million-$0.16-$0.13-28%
2018-06-302018-08-09$7.8 million-$0.15-$0.13-15.38%
2018-03-312018-05-10$6.57 million-$0.15-$0.06-150%
2017-12-312018-03-08$7.53 million-$0.17-$0.170%
2017-09-302017-11-09$6.09 million-$0.07-$0.05-40%
2017-06-302017-08-10$4.22 million-$0.05$0.04-219.75%
2017-03-312017-05-11$3.37 million-$0.05$0.01-600%
2016-12-312017-03-16$4.45 million-$0.06-$0.01-500%
2016-09-302016-11-10$3.94 million-$0.03
2016-06-302016-08-11$5.94 million$-0.00
2016-03-312016-05-12$7.33 million$0.01
2015-12-312016-03-17$4.36 million-$0.04
2015-09-302015-11-12$6.29 million$-0.00
2015-06-302015-08-13$6.1 million-$0.01
2015-03-312015-05-14$5.26 million-$0.03
2014-12-312015-03-19$4.24 million-$0.04
2014-09-302014-11-06$4.14 million-$0.02
2014-06-302014-08-12$3.86 million-$0.05
2014-03-312014-05-08$3.07 million-$0.06-$0.060%
2013-12-312014-03-27$2.4 million-$0.02-$0.0666.33%
2013-09-302013-11-22$2.72 million-$0.04
2013-06-302013-08-13$2.71 million-$0.03
2013-03-312013-05-10$2.34 million$0.05
2012-12-312013-03-29$3.52 million-$0.06-$0.1250%
2012-09-302012-11-08$3.63 million-$0.06-$0.1250%
2012-06-302012-08-09$2.67 million-$0.12
2012-03-312012-05-11$1.79 million-$0.16
2011-12-312012-03-14$1.81 million-$0.11
2011-09-302011-11-10$1.83 million-$0.10
2011-06-302011-08-11$1.94 million-$0.09
2011-03-312011-05-12$2.54 million-$0.06
2010-12-312011-03-16$2.03 million-$0.03
2010-09-302010-11-16$1.56 million-$0.03
2010-06-302010-08-17$2.03 million-$0.02
2010-03-312010-05-18$1.94 million$0.00
2009-12-312009-12-31-$0.01
2009-09-302009-09-30-$0.02
2009-06-302009-06-30-$0.03
2009-03-312009-03-31-$0.03
2008-12-312008-12-31-$0.07
2008-09-302008-09-30-$0.07
2008-06-302008-06-30-$0.08

ChromaDex Corporation (CDXC) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

ChromaDex Corporation (CDXC) Chart:

ChromaDex Corporation (CDXC) News:

Below you will find a list of latest news for ChromaDex Corporation (CDXC) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

ChromaDex Corporation (CDXC) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2024-06-212.50.9CALL0 50TRUE00
2024-06-2150.04CALL0 3230FALSE00
2024-06-217.50CALL0 00FALSE00
2024-06-212.50.05PUT0 200FALSE00
2024-06-2150PUT0 00TRUE00
2024-06-217.50PUT0 0859.09TRUE00
2024-07-192.50CALL0 0543.39TRUE00
2024-07-1950.05CALL0 1330FALSE00
2024-07-197.50CALL0 00FALSE00
2024-07-192.50PUT0 00FALSE00
2024-07-1950PUT0 00TRUE00
2024-07-197.50PUT0 0322.78TRUE00
2024-08-162.51.17CALL0 629341.15TRUE00
2024-08-1650.15CALL0 2930FALSE00
2024-08-167.50.15CALL0 1110FALSE00
2024-08-162.50.1PUT0 177115.42FALSE00
2024-08-1650PUT0 00TRUE00
2024-08-167.50PUT0 0162.9TRUE00
2024-11-152.52.05CALL0 500TRUE00
2024-11-1550.35CALL0 649109.54FALSE00
2024-11-157.50.21CALL0 4240FALSE00
2024-11-152.50.3PUT0 49975.52FALSE00
2024-11-1550PUT0 00TRUE00
2024-11-157.50PUT0 0196.81TRUE00

Latest CDXC Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST300$1.765
Jun 13, 2022 7:59 PM EST200$1.765
Jun 13, 2022 7:59 PM EST150$1.77
Jun 13, 2022 7:59 PM EST200$1.765
Jun 13, 2022 7:59 PM EST300$1.765

ChromaDex Corporation (CDXC) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-26424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1386570/000165495420007009/0001654954-20-007009-index.htm
2020-05-28UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1386570/000000000020004753/0000000000-20-004753-index.htm
2020-06-18UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1386570/000000000020005470/0000000000-20-005470-index.htm
2020-05-063Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1386570/000089924320012130/0000899243-20-012130-index.htm
2020-04-29SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1386570/000119312520125738/0001193125-20-125738-index.htm
2020-05-06SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1386570/000119312520134908/0001193125-20-134908-index.htm
2019-11-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1386570/000141588919001311/0001415889-19-001311-index.htm
2020-02-145Annual statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1386570/000141588920000337/0001415889-20-000337-index.htm
2020-02-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1386570/000141588920000544/0001415889-20-000544-index.htm
2020-02-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1386570/000141588920000546/0001415889-20-000546-index.htm
2020-02-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1386570/000141588920000548/0001415889-20-000548-index.htm
2020-02-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1386570/000141588920000550/0001415889-20-000550-index.htm
2020-03-313Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1386570/000141588920000901/0001415889-20-000901-index.htm
2020-05-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1386570/000141588920001263/0001415889-20-001263-index.htm
2020-05-20DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1386570/000141588920001280/0001415889-20-001280-index.htm
2020-06-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1386570/000141588920001659/0001415889-20-001659-index.htm
2020-06-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1386570/000141588920001661/0001415889-20-001661-index.htm
2020-06-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1386570/000141588920001663/0001415889-20-001663-index.htm
2020-06-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1386570/000141588920001667/0001415889-20-001667-index.htm
2020-06-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1386570/000141588920001675/0001415889-20-001675-index.htm
2020-06-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1386570/000141588920001677/0001415889-20-001677-index.htm
2020-11-064/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1386570/000141588920002554/0001415889-20-002554-index.htm
2020-11-064/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1386570/000141588920002556/0001415889-20-002556-index.htm
2020-11-064/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1386570/000141588920002558/0001415889-20-002558-index.htm
2020-11-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1386570/000141588920002560/0001415889-20-002560-index.htm
2019-10-02424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1386570/000165495419011370/0001654954-19-011370-index.htm
2019-10-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1386570/000165495419011618/0001654954-19-011618-index.htm
2019-11-1210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1386570/000165495419012698/0001654954-19-012698-index.htm
2019-11-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1386570/000165495419012705/0001654954-19-012705-index.htm
2019-11-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1386570/000165495419012708/0001654954-19-012708-index.htm
2020-01-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1386570/000165495420000291/0001654954-20-000291-index.htm
2020-03-1010-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1386570/000165495420002437/0001654954-20-002437-index.htm
2020-03-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1386570/000165495420002438/0001654954-20-002438-index.htm
2020-04-21DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1386570/000165495420004245/0001654954-20-004245-index.htm
2020-04-21DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1386570/000165495420004246/0001654954-20-004246-index.htm
2020-04-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1386570/000165495420004571/0001654954-20-004571-index.htm
2020-05-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1386570/000165495420005053/0001654954-20-005053-index.htm
2020-05-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1386570/000165495420005151/0001654954-20-005151-index.htm
2020-05-12NT 10-QNotification of inability to timely file Form 10-Q or 10-QSBhttps://www.sec.gov/Archives/edgar/data/1386570/000165495420005192/0001654954-20-005192-index.htm
2020-05-1810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1386570/000165495420005723/0001654954-20-005723-index.htm
2020-05-1810-K/AAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1386570/000165495420005725/0001654954-20-005725-index.htm
2020-05-21S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1386570/000165495420005879/0001654954-20-005879-index.htm
2020-05-28CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1386570/000165495420006038/0001654954-20-006038-index.htm
2020-05-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1386570/000165495420006116/0001654954-20-006116-index.htm
2020-06-03424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1386570/000165495420006270/0001654954-20-006270-index.htm
2020-06-12S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1386570/000165495420006554/0001654954-20-006554-index.htm
2020-06-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1386570/000165495420006880/0001654954-20-006880-index.htm
2020-06-24CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1386570/000165495420006907/0001654954-20-006907-index.htm
2020-06-26424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1386570/000165495420007009/0001654954-20-007009-index.htm
2020-07-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1386570/000165495420007469/0001654954-20-007469-index.htm
2020-08-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1386570/000165495420008588/0001654954-20-008588-index.htm
2020-08-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1386570/000165495420008596/0001654954-20-008596-index.htm
2020-08-18S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1386570/000165495420009302/0001654954-20-009302-index.htm
2020-11-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1386570/000165495420011832/0001654954-20-011832-index.htm
2020-11-0410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1386570/000165495420011840/0001654954-20-011840-index.htm
2019-10-02EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1386570/999999999519002229/9999999995-19-002229-index.htm
2020-06-01EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1386570/999999999520001306/9999999995-20-001306-index.htm
2020-06-26EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1386570/999999999520001689/9999999995-20-001689-index.htm
2019-10-24CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1386570/999999999719007343/9999999997-19-007343-index.htm
2019-10-24CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1386570/999999999719007344/9999999997-19-007344-index.htm
2020-03-19CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1386570/999999999720001256/9999999997-20-001256-index.htm
2020-03-24CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1386570/999999999720001268/9999999997-20-001268-index.htm
2020-03-24CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1386570/999999999720001269/9999999997-20-001269-index.htm
2020-04-02CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1386570/999999999720001314/9999999997-20-001314-index.htm
2020-05-26CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1386570/999999999720003131/9999999997-20-003131-index.htm
2020-08-17CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1386570/999999999720004403/9999999997-20-004403-index.htm
2020-09-11CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1386570/999999999720004631/9999999997-20-004631-index.htm
2020-10-28CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1386570/999999999720005163/9999999997-20-005163-index.htm

ChromaDex Corporation (CDXC) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of ChromaDex Corporation (CDXC). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 3796%
Institutional Ownership: 2512%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2020-05-19Robert N FriedCEOBuy1,000.004.694,690.001,393,314.00https://www.sec.gov/Archives/edgar/data/1386570/000141588920001263/0001415889-20-001263-index.htm
2019-11-14Robert N FriedCEOBuy10,000.003.0930,900.001,444,315.00https://www.sec.gov/Archives/edgar/data/1386570/000141588919001311/0001415889-19-001311-index.htm
2020-11-06KEVIN M FARRCHIEF FINANCIAL OFFICERBuy5,000.004.4322,150.0041,625.00https://www.sec.gov/Archives/edgar/data/1386570/000141588920002560/0001415889-20-002560-index.htm